
Understanding the Role of PPAR Agonists in PBC Care, with Aparna Goel, MD
In 2024 alone, the field of hepatology saw the addition of 2 new second-line treatment options for primary biliary cholangitis (PBC) with the FDA accelerated approvals of elafibranor (Iqirvo) and seladelpar (Livdelzi).1,2 A chronic and progressive …